Simplified meal management in adults using an advanced hybrid close loop system.


Journal

Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084

Informations de publication

Date de publication:
08 Aug 2024
Historique:
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: aheadofprint

Résumé

Background The advanced hybrid closed loop (AHCL) algorithm combines automated basal rates and corrections yet requires meal announcement for optimal performance, which poses a challenge for some. We aimed to compare glucose control in adults with T1D using the MiniMedTM 780G AHCL system utilizing simplified meal announcement versus precise carbohydrate counting. Methods In a study involving 14 adults with T1D, we evaluated glycemic control during a 13 week "precise phase", followed by two 3-4 week simplified meal announcement phases: "universal" (preset of one personalized fixed carbohydrate amount) and "incremental" (entry of multiples of one, two, or three of these presets depending on meal size estimate). Results Mean age was 45.7±12.4 and ten participants were male (71%). Mean baseline HbA1c was 6.8%±1.2% and TIR 67.5%±16.7%. Comparing the universal to the precise study phase, TIR was similar (75.4±13% vs. 77.7±9%, p=0.12) and GMI was slightly higher (6.8±0.4 vs. 6.6±0, p=0.01). Furthermore, there was less level 1 and 2 hypoglycemia (1.6±1% vs. 2.8±2%, p=0.03 and 0.3±5% vs. 0.65±1%, p=0.08), but slightly more level 1 and 2 hyperglycemia (17.1±8% vs. 15.0±7%, p=0.05 and 5.5±5% vs. 3.6±3%, p=0.04). When comparing the incremental to the precise phase, GMI was identical (6.6%) and TIR superior (80.5±10% vs. 77.7±9%, p=0.02). Additionally, there was less level 1 hypoglycemia (1.9±1% vs. 2.8±2%, p=0.01) and a trend for less level 2 hypoglycemia (0.4±0.7% vs. 0.65±1%, p=0.08). Conclusions A simplified meal announcement strategy in adults using the MiniMedTM780G system, relying on three increments of a universal CHO amount, may offer a way to improve glycemic control and ease self-care. For patients with more limitations, using one universal CHO amount could be a safe alternative meeting most consensus glycemic targets.

Identifiants

pubmed: 39115922
doi: 10.1089/dia.2024.0224
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Noga Minsky (N)

Sheba Medical Center at Tel Hashomer, Division of Endocrinology, Diabetes and Metabolism, Derech Sheba 2, Ramat-gan, Tel Aviv, Israel, 52621; Noga.Minsky@gmail.com.

Roy Shalit (R)

Sheba Medical Center at Tel Hashomer, Division of Endocrinology, Diabetes and Metabolism, Derech Sheba 2, Ramat Gan, Israel, Tel Hashomer, Israel, 5262100; rshalit@gmail.com.

Andrea Benedetti (A)

Medtronic, Closed-loop Development, Northridge, California, United States; andrea.benedetti@medtronic.com.

Maya Laron-Hirsh (M)

Sheba Medical Center at Tel Hashomer, Division of Endocrinology, Diabetes and Metabolism, Tel Hashomer, Tel Aviv, Israel; Maya.Laron-Hirsh@sheba.health.gov.il.

Ohad Cohen (O)

Sheba Medical Center at Tel Hashomer, Division of Diabetes, Endocrinology and Metabolism, Tel Hashomer, Tel Aviv, Israel.
Tel Aviv University, Faculty of Medicine, Tel Aviv, Tel Aviv, Israel.
Medtronic, Closed-loop Development, Northridge, California, United States; ohad.cohen@medtronic.com.

Natalie Kurtz (N)

Medtronic, Closed-loop Development, Northridge, California, United States; natalie.kurtz@medtronic.com.

Anirban Roy (A)

Medtronic, Closed-loop Development, 18000 Devonshire Street, Northridge, California, United States, 91325; anirban.roy@medtronic.com.

Benyamin Grosman (B)

Medtronic, Closed-loop Development, 18000 Devomshire st, Northridge, California, United States, 91325; benyamin.grosman@medtronic.com.

Amir Tirosh (A)

Sheba Medical Center at Tel Hashomer, Division of Endocrinology, Diabetes and Metaboilism, Tel Hashomer, Tel Aviv, Israel.
Tel Aviv University, Faculty of Medicine, Tel Aviv, Tel Aviv, Israel; Amir.Tirosh@sheba.health.gov.il.

Classifications MeSH